Biomarkers of vascular function in premenopausal and recent postmenopausal women of similar age: Effect of exercise training

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 306, Issue 7, 2014, Pages

  Nyberg, Michael ^a   Seidelin, Kaare ^a   Andersen, Thomas Rostgaard ^a   Overby, Nickie Neumann ^a   Hellsten, Ylva ^a   Bangsbo, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endothelin 1; Estrogen; Prostanoids; Soluble intercellular adhesion molecule 1

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; BIOLOGICAL MARKER; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIN 1; FOLLITROPIN; INTERCELLULAR ADHESION MOLECULE 1; LUTEINIZING HORMONE; PROGESTERONE; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; THROMBOXANE SYNTHASE; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR EFFECT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EXERCISE; FEMALE; HORMONE DETERMINATION; HUMAN; MEASUREMENT; MIDDLE AGED; OXYGEN CONSUMPTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

ENDOTHELIN-1; ESTROGEN; PROSTANOIDS; SOLUBLE INTERCELLULAR ADHESION MOLECULE-1;

6-KETOPROSTAGLANDIN F1 ALPHA; ADIPOSITY; AGE FACTORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD VESSELS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P-450 ENZYME SYSTEM; ENDOTHELIN-1; EXERCISE; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTRAMOLECULAR OXIDOREDUCTASES; MIDDLE AGED; MUSCLE, SKELETAL; OXYGEN CONSUMPTION; POSTMENOPAUSE; PREMENOPAUSE; THROMBOXANE-A SYNTHASE; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84900535035     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00539.2013     Document Type: Article

References (43)

1. Abu-Taha M, Rius C, Hermenegildo C, Noguera I, Cerda-Nicolas JM, Issekutz AC, Jose PJ, Cortijo J, Morcillo EJ, Sanz MJ. Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan. J Immunol 183: 1393-1402, 2009.
2. Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K. Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation 94: 61-66, 1996.
3. Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest 35: 609-616, 1975.
4. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J Am Coll Cardiol 54: 2374-2375, 2009.
5. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25: 305-313, 1995.
6. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 24: 471-476, 1994.
7. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ. Endothelial function and dysfunction. Part I. Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 23: 7-17, 2005.
8. Ehrlich JR, Kaluzny M, Baumann S, Lehmann R, Hohnloser SH. Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation. Clin Res Cardiol 100: 1029-1036, 2011.
9. Gambacciani M, Rosano GM, Monteleone P, Fini M, Genazzani AR. Clinical relevance of the HERS trial. Lancet 360: 641, 2002.
10. Gliemann L, Schmidt JF, Olesen J, Bienso RS, Peronard SL, Grandjean SU, Mortensen SP, Nyberg M, Bangsbo J, Pilegaard H, Hellsten Y. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J Physiol 591: 5047-5059, 2013.
11. Gross MD, Bielinski SJ, Suarez-Lopez JR, Reiner AP, Bailey K, Thyagarajan B, Carr JJ, Duprez DA, Jacobs DR Jr. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults Study. Clin Chem 58: 411-420, 2012.
12. Hartanto MD, Arieselia Z, Setiabudy R, Setiawati A, Baziad A. Urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin-F1 alpha in healthy post-menopausal and pre-menopausal women receiving aspirin 100 mg. J Thromb Thrombolysis 34: 79-84, 2012.
13. Hilden T. The influence of arterial compliance on diastolic blood pressure and its relation to cardiovascular events. J Hum Hypertens 5: 131-135, 1991.
14. Hodis HN, St John JA, Xiang M, Cushman M, Lobo RA, Mack WJ. Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). Am J Cardiol 101: 1131-1133, 2008.
15. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85: 447-452, 1976.
16. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 109: II27-II33, 2004.
17. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 118: 2047-2056, 2008.
18. Lee IM, Sesso HD, Oguma Y, Paffenbarger RS Jr. Relative intensity of physical activity and risk of coronary heart disease. Circulation 107: 1110-1116, 2003.
19. Lekontseva O, Chakrabarti S, Davidge ST. Endothelin in the female vasculature: a role in aging? Am J Physiol Regul Integr Comp Physiol 298: R509-R516, 2010.
20. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903-1913, 2002.
21. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 169: 203-214, 2003.
22. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, Sutton-Tyrrell K. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol 54: 2366-2373, 2009.
23. Mumford SL, Dasharathy S, Pollack AZ, Schisterman EF. Variations in lipid levels according to menstrual cycle phase: clinical implications. Clin Lipidol 6: 225-234, 2011.
24. Novella S, Dantas AP, Segarra G, Medina P, Hermenegildo C. Vascular aging in women: is estrogen the fountain of youth? Front Physiol 3: 165, 2012.
25. Nyberg M, Mortensen SP, Hellsten Y. Physical activity opposes the age-related increase in skeletal muscle and plasma endothelin-1 levels and normalizes plasma endothelin-1 levels in individuals with essential hypertension. Acta Physiol (Oxf) 207: 524-535, 2013.
26. Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sports 16 Suppl 1: 3-63, 2006.
27. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol 140: 665-673, 1992.
28. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation 117: 823-831, 2008.
29. Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 170: 12-23, 2009.
30. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
31. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126, 1999.
32. Rossouw JE. Effect of postmenopausal hormone therapy on cardiovascular risk. J Hypertens Suppl 20: S62-S65, 2002.
33. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465-1477, 2007.
34. Sobrino A, Oviedo PJ, Novella S, Laguna-Fernandez A, Bueno C, Garcia-Perez MA, Tarin JJ, Cano A, Hermenegildo C. Estradiol selectively stimulates endothelial prostacyclin production through estrogen receptor-α. J Mol Endocrinol 44: 237-246, 2010.
35. Sudhir K, Ko E, Zellner C, Wong HE, Hutchison SJ, Chou TM, Chatterjee K. Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation 96: 3626-3632, 1997.
36. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 29: 274-279, 1997.
37. Taddei S, Virdis A, Ghiadoni L, Mattei P, Sudano I, Bernini G, Pinto S, Salvetti A. Menopause is associated with endothelial dysfunction in women. Hypertension 28: 576-582, 1996.
38. Testa M, Rocca B, Spath L, Ranelletti FO, Petrucci G, Ciabattoni G, Naro F, Schiaffino S, Volpe M, Reggiani C. Expression and activity of cyclooxygenase isoforms in skeletal muscles and myocardium of humans and rodents. J Appl Physiol 103: 1412-1418, 2007.
39. Thijssen DH, Rongen GA, Smits P, Hopman MT. Physical (in)activity and endothelium-derived constricting factors: overlooked adaptations. J Physiol 586: 319-324, 2008.
40. Tostes RC, Nigro D, Fortes ZB, Carvalho MH. Effects of estrogen on the vascular system. Braz J Med Biol Res 36: 1143-1158, 2003.
41. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112: 976-983, 2005.
42. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847, 1998.
43. Wisloff U, Stoylen A, Loennechen JP, Bruvold M, Rognmo O, Haram PM, Tjonna AE, Helgerud J, Slordahl SA, Lee SJ, Videm V, Bye A, Smith GL, Najjar SM, Ellingsen O, Skjaerpe T. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 115: 3086-3094, 2007.